Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TARS | US
1.23
1.68%
Healthcare
Biotechnology
30/06/2024
09/03/2026
74.49
72.65
74.77
72.35
Tarsus Pharmaceuticals Inc. a biopharmaceutical company focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03 a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition the company develops lotilaner to address diseases across therapeutic categories in human medicine including eye care dermatology and other diseases. Tarsus Pharmaceuticals Inc. was incorporated in 2016 and is headquartered in Irvine California.
View LessLow Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
High Short-term Volatility
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
54.1%1 month
47.9%3 months
39.7%6 months
43.0%-
-
5.59
0.29
0.19
-3.23
13.90
-
-155.27M
2.83B
2.83B
-
-81.60
-
1.00K
-75.04
14.63
27.12
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
14.25
Range1M
19.46
Range3M
24.71
Rel. volume
0.62
Price X volume
30.22M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Denali Therapeutics Inc | DNLI | Biotechnology | 21.31 | 3.05B | 8.23% | n/a | 3.51% |
| iShares $ Corp Bond ETF USD Dist | LQDA | Biotechnology | 35.87 | 3.03B | -0.44% | n/a | 4.70% |
| IDEAYA Biosciences Inc | IDYA | Biotechnology | 35.08 | 2.96B | 5.69% | n/a | 0.20% |
| ARCUTIS BIOTHERAPEUTICS INC. | ARQT | Biotechnology | 24.82 | 2.90B | 3.42% | n/a | 111.34% |
| NewAmsterdam Pharma Company N.V. Ordinary Shares | NAMS | Biotechnology | 30.77 | 2.77B | 3.05% | n/a | 0.15% |
| Edgewise Therapeutics Inc. | EWTX | Biotechnology | 28.66 | 2.69B | 3.02% | n/a | 0.98% |
| Spruce Biosciences Inc | SPRB | Biotechnology | 62.11 | 2.57B | 11.17% | n/a | 6.24% |
| Veracyte Inc | VCYT | Biotechnology | 33.37 | 2.56B | -1.42% | n/a | 1.83% |
| DBV Technologies S.A | DBVT | Biotechnology | 22.9 | 2.44B | 4.71% | n/a | 16.59% |
| Apellis Pharmaceuticals Inc | APLS | Biotechnology | 19.99 | 2.43B | -0.40% | n/a | 179.52% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Polaris Industries Inc | PII | Recreational Vehicles | 52.73 | 2.94B | -2.96% | 14.48 | 170.51% |
| Harley-Davidson Inc | HOG | Recreational Vehicles | 18.77 | 2.47B | -2.29% | 7.33 | 218.58% |
| HNI Corporation | HNI | Building Products & Equipment | 41.37 | 1.95B | -0.17% | 22.12 | 76.47% |
| Pitney Bowes Inc | PBI | Building Products & Equipment | 10.67 | 1.92B | 0.85% | n/a | -571.93% |
| ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 14.07 | 1.41B | 1.22% | n/a | 19.46% |
| Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 36.22 | 1.14B | 1.06% | 51.60 | 88.92% |
| Winnebago Industries Inc | WGO | Recreational Vehicles | 35.25 | 1.02B | -2.87% | 22.53 | 56.33% |
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.39 | 783.29M | 1.89% | 11.62 | 116.21% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 6.31 | 729.29M | 0.16% | 65.18 | 77.00% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 16.37 | 682.35M | 0.37% | 42.05 | 64.69% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.23 | - | Cheaper |
| Ent. to Revenue | 13.90 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 5.59 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 39.68 | - | Lower Risk |
| Debt to Equity | 0.29 | -1.23 | Expensive |
| Debt to Assets | 0.19 | 0.25 | Cheaper |
| Market Cap | 2.83B | - | Emerging |